Abstract Controlled human infection models (CHIM) provide a crucial platform for evaluating influenza countermeasures. This dose-escalation, double-blind, randomized, placebo-controlled study aimed to establish the optimal infectious dose of a recombinant influenza A/Texas/71/2017 (H3N2) challenge strain. Healthy adults aged 18–45 received sham inoculum or 10⁴, 10⁵, or 10⁶ median tissue culture infectious dose (TCID₅₀) of challenge virus and were monitored for 7 days.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Sarah
Contact Sarah, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack